Africa Collaboration Country Study reference Population Cohort participants Sample size (n) Age range (years) % Male Creatinine measurement method eGFR range Proteinuria/ albuminuria Burkina Faso† Ali et al62 GP Geographical cohort 2072 38–69 50.4 Jaffe 11.8 to >90 Albuminuria Burundi Cailhol et al27 HIV HIV clinic cohort 300 19–66 29.7 Jaffe 6.0 to >90 Proteinuria Cameroon Choukem* DM Diabetes clinic cohort 790 19–82 65.0 Jaffe 1.7 to >90 NA Cameroon Feteh et al57 DM Diabetes clinic cohort 645 20–86 53.0 Jaffe 4.0 to >90 NA Cameroon Kaze* GP Geographical cohort 433 21–90 49.0 Modified Jaffe 6.9 to >90 Albuminuria Cameroon Kaze et al45 GP Geographical cohort 500 19–83 53.4 Modified Jaffe 23.0 to >90 Albuminuria Cameroon Kaze et al46 GP Geographical cohort 439 19–90 42.1 Modified Jaffe 12.0 to >90 Albuminuria Cameroon Kaze et al56 HPT HPT clinic cohort 336 33–90 36.6 Modified Jaffe 5.0 to >90 Albuminuria Egypt Gouda et al25 Other FDR of CKD cohort 416 18–75 43.2 Jaffe 32.0 to >90 Albuminuria Ghana‡ Adjei et al40 GP Geographical cohort 2543 25–96 33.0 Jaffe 15.5 to >90 Albuminuria Ghana Chadwick et al53 HIV HIV clinic cohort 677 20–77 26.1 Jaffe 9.8 to >90 Proteinuria Ghana Osafo et al55 HPT HPT clinic cohort 754 19–90 21.3 Jaffe 1.4 to >90 Proteinuria Ghana† Ali et al62 GP Geographical cohort 2011 40–61 45.8 Jaffe 12.3 to >90 Albuminuria Kenya† Ali et al62 GP Geographical cohort 2000 35–67 46.0 Jaffe 13.9 to >90 Albuminuria Nigeria Adedeji et al51 HIV HIV clinic cohort 304 18–80 54.7 Modified Jaffe 5.9 to >90 Albuminuria Nigeria Alasia et al26 Other Renal clinic cohort 605 18–86 49.3 Jaffe 1.3 to >90 Proteinuria Nigeria Ayodele* GP Cohort of students 307 18–30 35.8 Modified Jaffe 39.9 to >90 NA Nigeria Ayodele* GP Geographical cohort 419 19–80 40.3 Modified Jaffe 37.1 to >90 NA Nigeria Ayokunle et al52 HIV HIV clinic cohort 335 20–75 43.9 Jaffe 4.7 to >90 Albuminuria Nigeria Okoye et al32 GP Geographical cohort 476 18–90 33.8 Modified Jaffe 22.4 to >90 Proteinuria Nigeria Oluyombo et al33 GP Geographical cohort 972 18–100 30.4 Modified Jaffe 23.9 to >90 Albuminuria Nigeria Raji et al58 Other Renal clinic cohort 309 18–73 45.3 Modified Jaffe 1.2 to >90 NA RoC Ekat et al29 HIV HIV clinic cohort 562 18–64 33.8 Jaffe 4.0 to >90 NA SA Adeniyi et al39 GP Cohort of teachers 455 22–71 29.7 Modified Jaffe 32.4 to >90 Proteinuria SA Malan et al GP Cohort of teachers 409 20–65 49.4 Jaffe 1.3 to >90 Albuminuria SA Matsha et al31 GP Geographical cohort 1620 18–91 24.8 Jaffe 8.2 to >90 Albuminuria SA Peer et al34 GP Geographical cohort 1086 22–81 35.9 Jaffe 9.0 to >90 NA SA Rayner and Becker35 HPT HPT clinic cohort 1107 18–94 48.8 NA NA Albuminuria SA Schutte et al37 GP Geographical cohort 750 20–70 46.1 Jaffe 47.8 to >90 NA SA Schutte et al49 GP Geographical cohort 1202 20–30 48.1 Jaffe 48.1 to >90 Albuminuria SA† Ali et al62 GP Geographical cohort 2312 40–81 42.2 Jaffe 3.1 to >90 Albuminuria SA† Ali et al62 GP Geographical cohort 1388 29–82 30.6 Jaffe 4.8 to >90 Albuminuria SA† Ali et al62 GP Geographical cohort 1918 39–61 50.6 Jaffe 9.4 to >90 Albuminuria Seychelles Pruijm et al38 GP Geographical cohort 1230 25–64 46.2 Jaffe 3.2 to >90 Albuminuria Continued on July 8, 2022 by guest. Protected by copyright. http://gh.bmj.com/ BMJ Glob Health: first published as 10.1136/bmjgh-2021-006454 on 4 August 2021. Downloaded from 6 George C, et al. BMJ Global Health 2021; 6:e006454. doi:10.1136/bmjgh-2021-006454 BMJ Global Health potential confounders of the associations between kidney function and outcomes including, but not limited to, age, ethnicity, smoking, medical history and treatment, and comorbidities like diabetes mellitus, hypertension, and obesity. Given the timeframe, we have made considerable prog - ress in establishing the consortium, with included studies covering a fair proportion of Africa. EXPANDING THE CONSORTIUM As a means of strengthening the network we plan to engage with the African Renal Association and the International Society of Nephrology’s Africa Regional Board, to form a broader platform which would assist in calls for funding for this project as well as funding of needed prevalence studies in the rest of Africa not yet represented in the consortium. Also, we have scheduled a process of updating our systematic search process to identify new studies every 6months, as a means of expanding our database. Expansion of the consortium is indeed important to obtain a representative group of study participants and sufficient statistical power for the results to be mean - ingful, but we are cautious to not stretch resources too thin and risk failure of the project. We also recognised early on that a balance needed to be struck between awaiting adequate IPD to generate sufficiently powered evidence and getting this evidence out to policymakers and other researchers; bearing in mind that potential collaborators and funders are more likely to join and fund a successful consortium. Interested research groups working in the field of CKD are welcome to join the network, by contacting the Country Study reference Population Cohort participants Sample size (n) Age range (years) % Male Creatinine measurement method eGFR range Proteinuria/ albuminuria Seychelles Heiniger et al63 GP Geographical cohort 1240 26–64 42.8 Jaffe 4.5 to